Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Aarsleff unit Wicotec Kirkebjerg agrees to buy Rent-Tech, subsidiaries for up to DKK 597.5 million

Aarsleff unit Wicotec Kirkebjerg agrees to buy Rent-Tech, subsidiaries for up to DKK 597.5 million

BitgetBitget2026/09/29 04:57
  • Wicotec Kirkebjerg, part of Per Aarsleff Holding, agreed to buy West Zealand-based Rent-Tech for up to DKK 597.5 million.
  • Deal includes subsidiaries Multi-Tech and Asger G. Jørgensen, along with a 50.5% stake in El-Centret Højby.
  • Targets posted about DKK 700 million revenue in 2025, with EBIT of DKK 88 million.
  • Transaction structure combines cash at completion with a performance-based contingent payment, on a cash- and debt-free basis.
  • Closing expected in Q4 2026, with completion no earlier than the start of the 2026/27 financial year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Per Aarsleff Holding A/S published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Uncertainty clouds the US stock IPO market as smart ring manufacturer Oura (OURA.US) joins the ranks of delayed listings

Oura (OURA.US) has become the latest company to postpone its initial public offering (IPO) in the United States due to market uncertainty.

智通财经•2026/09/29 11:36

AstraZeneca (AZN.US) invests in Summit (SMMT.US), gaining positive outlooks from JPMorgan and Citi: Cancer drug strategy awaits validation

Analysts from JPMorgan and Citi have welcomed the deal between AstraZeneca and Summit Therapeutics, stating that it aligns with AstraZeneca's cancer strategy.

智通财经•2026/09/29 11:06